 | ||
 |
 |
 |
 |
 |
 |
|
Central venous catheter coatings
Biofilm problem:
Catheter blood stream infections caused by biofilms forming on central venous catheter surfaces.
Market size:
The US $300 million US market for venous access catheters is made up of 75% non-coated catheters. The rate of catheterization increases the rate of blood stream infections, each costing the healthcare system over $14,000.
Kane Biotech solution:
A DispersinB™ antimicrobial combination for coating central venous catheters for bacterial control and biofilm prevention and dispersal.
Technology status:
Kane Biotech’s lead central venous catheter coating product has demonstrated its efficacy and broad spectrum activity in preventing catheter related infections in vitro and in vivo.
Pre-clinical results: In vitro effect of a DiserpsinB™ antimicrobial combination on a cross-section of pathogens
Prevention of catheter colonization by S. aureus
The use of central venous catheters (CVCs) is common in today’s medical world. While the CVC is a necessary part of treatment, its use also puts patients at serious risk of local and systematic complications due to infection.
There are more than five million CVCs used in the US each year, and each blood stream infection in an intensive care unit costs the health care system more than $35,000 per episode.
Hospitals are under pressure to reduce these infections and the use of antibiotic coatings is prevalent based upon the immediate health risks posed by these types of infections. Similar to urinary tract infections (UTI), the infection rate is linked to catheterization, as the catheter provides the platform for bacterial adherence and biofilm formation.
Kane Biotech’s lead coating for reducing infections associated with central venous catheters is a DispersinB™ antimicrobial combination. In a recent study, the Company was able to demonstrate that this DispersinB™ antimicrobial combination for coating catheters performed better than both the market-leading coated catheters, and uncoated control catheters in preventing catheter colonization by the pathogen Staphylococcus aureus (S. aureus). More specifically, 29 of 30 (96.7%) catheter segments coated with this combination remained free of colonization by S. aureus, compared to 26 of 30 (86.7%) of the market leading coated catheters and only 1 of 30 (3.3%) of the uncoated catheters. Furthermore, the study showed that this DispersinB™ antimicrobial combination coated CVCs were as good at reducing catheter colonization by S. aureus as the market leading coated CVC at its highest antimicrobial concentration level.
In addition, Kane has performed in vitro studies that demonstrate this DispersinB™ antimicrobial combination is superior to the market leading coated catheter not only against S. aureus, but also against Staphylococcus epidermidis and Candida albicans, the three most significant pathogens in catheter related blood stream infections.
This DispersinB™ antimicrobial combination is a proprietary combination offering dual action, synergistic protection against blood stream infections. Our DispersinB™ technology prevents and disperses biofilms while the antimicrobial agent offers broad spectrum microbial control. As a non-antibiotic technology, this combination is a compelling technology for controlling device related infections in the clinical setting.
